<scp>GSK</scp>‐3β activation mediates apolipoprotein <scp>E4</scp>‐associated cognitive impairment in type 2 diabetes mellitus: A multicenter, cross‐sectional study

Yang Gao, Haitao Yu, Yanchao Liu, Zhipeng Xu, Benrong He, Honghai Liu, Yuying Wang, Yao Zhang, Yi Liang, Ying Yang, Jie Zheng, Jian‐Zhi WangJournal of Diabetes 2023 · DOI

TL;DR

This study reveals that a specific genetic variant, ApoE ε4, exacerbates cognitive decline in individuals with Type 2 Diabetes Mellitus (T2DM) by increasing the activity of the enzyme GSK-3β. This finding suggests that targeting GSK-3β with inhibitors could be a promising therapeutic strategy to preserve cognitive function in T2DM patients, particularly those with the ApoE ε4 genotype.

What Problem Does This Paper Address?

Type 2 Diabetes Mellitus (T2DM) is a known risk factor for Alzheimer's disease (AD) and dementia, sharing several pathological features with AD, such as insulin resistance and neurodegeneration. Apolipoprotein E (ApoE) genotype is a significant genetic contributor to late-onset AD, with the ε4 allele being a risk factor and the ε2 allele being protective. While both T2DM and AD are associated with cognitive decline, and ApoE ε4 is linked to AD, the specific role of ApoE ε4 in cognitive impairment within the T2DM population, and the underlying molecular mechanisms, remain unclear. Glycogen synthase kinase-3β (GSK-3β) is a key enzyme implicated in both insulin resistance and AD-like pathologies, making it a potential mediator. This paper investigates whether GSK-3β activity links ApoE ε4 to cognitive impairment in T2DM patients.

Methods

The researchers conducted a multicenter, cross-sectional study involving 1139 T2DM patients. They assessed:

  • ApoE Genotyping: Determining the specific ApoE allele (ε2, ε3, or ε4) for each participant.
  • GSK-3β Activity Measurement: Quantifying the activity of GSK-3β in platelets. Platelets were chosen due to their biological similarities with neurons and their potential as peripheral biomarkers. Total GSK-3β and its inactive phosphorylated form (pS9) were measured, and the ratio was used to indicate activity.
  • Cognitive Function Assessment: Using the Mini-Mental State Examination (MMSE) to evaluate cognitive function. Patients were categorized as cognitively normal (CN), mild cognitive impairment (MCI), or moderate dementia (MD) based on MMSE scores.

Statistical analyses included:

  • ANOVA and Kruskal-Wallis tests: To compare demographic and clinical characteristics across ApoE genotype groups.
  • Logistic Regression: To assess the independent association between ApoE polymorphism and cognitive impairment, adjusting for various clinical factors.
  • Linear Regression: To examine the association between ApoE genotypes and GSK-3β activity.
  • Spearman Correlation: To analyze the relationship between GSK-3β activity and cognitive scores, as well as other clinical variables.
  • Mediation Analysis (Baron and Kenny model): To determine if GSK-3β activity mediates the relationship between ApoE ε4 and cognitive impairment.

Datasets

The study utilized data from 1139 T2DM patients recruited from five medical centers in Wuhan, China, between January 2012 and November 2018. This constitutes a newly collected dataset for this specific research question.

Key Insights and Ideas

  • ApoE ε4 is a risk factor for cognitive impairment in T2DM: The study confirms that carrying the ApoE ε4 allele is associated with poorer cognitive function (lower MMSE scores) in T2DM patients, independent of other clinical factors. This is particularly pronounced in female patients and those in the mid-life age group.
  • GSK-3β activity is elevated in ApoE ε4 carriers with cognitive impairment: Patients with the ApoE ε4 genotype and cognitive impairment showed significantly higher platelet GSK-3β activity compared to ε3 carriers. This suggests a direct link between the genetic risk factor and the enzymatic pathway.
  • GSK-3β acts as a mediator: The mediation analysis strongly indicates that elevated GSK-3β activity is the mechanism through which ApoE ε4 contributes to cognitive impairment in T2DM. When GSK-3β's role was accounted for, the direct link between ApoE ε4 and cognitive impairment became non-significant.
  • Platelet GSK-3β as a potential biomarker: The study reinforces the idea that platelet GSK-3β activity can serve as a peripheral biomarker for cognitive decline in T2DM, aligning with previous research.
  • ApoE ε2's role is less clear: While ApoE ε4 showed a clear association, the ε2 allele did not demonstrate a significant association with cognitive function or GSK-3β activity in this cohort, though some previous studies suggest a protective role.

Key Results

  • ApoE ε4 carriers showed significantly reduced MMSE scores compared to ε3 carriers (p = .0006).
  • ApoE ε4 carriers had significantly increased platelet GSK-3β activity compared to ε3 carriers (p = .03).
  • Logistic regression analysis showed that ApoE ε4 was independently associated with a higher risk of cognitive impairment (OR = 1.733, p = .010) after adjusting for multiple clinical factors.
  • Linear regression analysis revealed that ApoE ε4 genotype was independently associated with increased GSK-3β activity (β = 0.235, p = .007) after adjustments.
  • Mediation analysis demonstrated that GSK-3β activation significantly mediated the association between ApoE ε4 and cognitive impairment. The direct effect of ApoE ε4 on cognitive impairment became non-significant (c' = -0.327, p = .073) when GSK-3β was included as a mediator.
  • T2DM patients with cognitive impairment showed significantly increased GSK-3β activity compared to those with normal cognition (p < .0001).

Limitations and Future Work

The authors acknowledge several limitations:

  • Cross-sectional design: This limits the ability to establish definitive causal relationships. Longitudinal studies are needed to confirm these findings.
  • Han population in Wuhan: The study's findings are limited to a specific ethnic and geographic group, and generalization to other populations may not be appropriate. Replication in diverse ethnic groups is recommended.
  • Potential for residual confounders: Despite adjustments, unmeasured factors could still influence the observed associations.

Future work suggested includes:

  • Longitudinal studies: To track cognitive changes over time and confirm the causal role of GSK-3β.
  • Cerebrospinal fluid or brain tissue analysis: To provide more direct evidence of GSK-3β's role in the central nervous system.
  • In vitro and animal studies: To further elucidate the molecular mechanisms linking ApoE ε4, GSK-3β, and cognitive impairment.
  • Investigating peripheral insulin homeostasis: Understanding how it influences CNS function is highlighted as an important future direction.
  • Clinical trials of GSK-3β inhibitors: The study strongly suggests that GSK-3β inhibitors could be a therapeutic strategy, but their effectiveness needs to be proven in clinical trials.

Summary updated

Abstract

We reported here that the upregulation of GSK-3β activity mediates the exacerbation of cognitive impairment by ApoE ε4-enhanced cognitive impairment in T2DM patients, suggesting GSK-3β inhibitors as promising drugs for preserving cognitive function in T2DM patients, especially to those with ApoE ε4 genotype.
BibTeX
@article{gao2023scp,
  author = {Yang Gao and Haitao Yu and Yanchao Liu and Zhipeng Xu and Benrong He and Honghai Liu and Yuying Wang and Yao Zhang and Yi Liang and Ying Yang and Jie Zheng and Jian‐Zhi Wang},
  title = {{<scp>GSK</scp>‐3β activation mediates apolipoprotein <scp>E4</scp>‐associated cognitive impairment in type 2 diabetes mellitus: A multicenter, cross‐sectional study}},
  journal = {Journal of Diabetes},
  year = {2023},
  doi = {10.1111/1753-0407.13470},
}
Figure